Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients (Q24246468)

6

0 references

Mical Paul

1

0 references

Liat Vidal

4

0 references

Sara Borok

2

object named as

Sara Borok

0 references

Abigail Fraser

3

object named as

Abigail Fraser

0 references

author name string

Michal Cohen

Cochrane Database of Systematic Reviews

5

0 references

publication date

20 July 2005

0 references

published in

0 references

cites work

Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Vancomycin does not benefit persistently febrile neutropenic people with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Prospective randomized clinical trial of teicoplanin for empiric combined antibiotic therapy in febrile, granulocytopenic acute leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Empiric antimicrobial therapy in febrile granulocytopenic patients. Randomized prospective comparison of amikacin plus piperacillin with or without parenteral trimethoprim/sulphamethoxazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Options and limitations of teicoplanin in febrile granulocytopenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Early identification of neutropenic patients at risk of grampositive bacteraemia and the impact of empirical administration of vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Treatment of severe sepsis in bone marrow transplant recipients with teicoplanin in combination with β-lactams and aminoglycosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamicin-carbenicillin in febrile granulocytopenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

A randomized prospective study of ceftazidime and ciprofloxacin with or without teicoplanin as an empiric antibiotic regimen for febrile neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Piperacillin plus amikacin vs. piperacillin plus amikacin plus teicoplanin for empirical treatment of febrile episodes in neutropenic patients receiving quinolone prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Teicoplanin as modification of initial empirical therapy in febrile granulocytopenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Tre

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Granulocytopenia in hospitalized patients. II. A prospective comparison of two antibiotic regimens in the empiric therapy of febrile patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Interventional antimicrobial strategy in febrile neutropenic patients. Results of a multicenter study in 1,260 patients with hematological malignancies. The Interventional Antimicrobial Strategy Study Group, Paul Ehrlich Society for Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

Aztreonam therapy in neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

7 January 2021

Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

7 January 2021

Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

7 January 2021

From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

7 January 2021

Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

7 January 2021

A randomized study of tobramycin plus ticarcillin, tobramycin plus cephalothin and ticarcillin, or tobramycin plus mezlocillin in the treatment of infection in neutropenic patients with malignancies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

7 January 2021

Ceftazidime with or without vancomycin vs. cephalothin, carbenicillin and gentamicin as the initial therapy of the febrile neutropenic pediatric cancer patient.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

7 January 2021

Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

7 January 2021

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Re

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

7 January 2021

Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. The International Antimicrobial Therapy Project Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

7 January 2021

Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003914.PUB2

7 January 2021

10.1002/14651858.CD003914.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3504438

OpenCitations bibliographic resource ID

3504438

1 reference